Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer

The effect of bevacizumab plus paclitaxel therapy on progression-free survival (PFS) is prominent; however, no overall survival (OS) benefit has been demonstrated. Our aim was to study the predictive efficacy of peripheral immune-related parameters, neutrophil-to-lymphocyte ratio (NLR), absolute lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyagawa, Yoshimasa, Yanai, Ayako, Yanagawa, Takehiro, Inatome, Junichi, Egawa, Chiyomi, Nishimukai, Arisa, Takamoto, Kaori, Morimoto, Takashi, Kikawa, Yuichiro, Suwa, Hirofumi, Taji, Tomoe, Yamaguchi, Ai, Okada, Yuki, Sata, Atsushi, Fukui, Reiko, Bun, Ayako, Ozawa, Hiromi, Higuchi, Tomoko, Fujimoto, Yukie, Imamura, Michiko, Miyoshi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967770/
https://www.ncbi.nlm.nih.gov/pubmed/32002126
http://dx.doi.org/10.18632/oncotarget.27423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967770/
https://www.ncbi.nlm.nih.gov/pubmed/32002126
http://dx.doi.org/10.18632/oncotarget.27423

Ejemplares similares